Lorbrena — Revenues:
Pfizer Lorbrena — Revenues: increased by 8.2% to $305.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 37.4%, from $222.00M to $305.00M. Over 4 years (FY 2021 to FY 2025), Lorbrena — Revenues: shows an upward trend with a 40.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market penetration, successful clinical adoption, or expanded label indications for the therapy, while a decrease may signal increased competition, patent expiration, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross sales generated by a specific oncology pharmaceutical product line within the com...
Peer comparison
Comparable to revenue metrics for specific branded specialty drugs or targeted therapies at other large-cap pharmaceutical companies, often evaluated against the broader oncology portfolio performance.
pfe_segment_lorbrena_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $66.00M | $67.00M | $73.00M | $72.00M | $77.00M | $99.00M | $96.00M | $112.00M | $121.00M | $159.00M | $146.00M | $164.00M | $169.00M | $206.00M | $193.00M | $222.00M | $251.00M | $268.00M | $282.00M | $305.00M |
| QoQ Change | — | +1.5% | +9.0% | -1.4% | +6.9% | +28.6% | -3.0% | +16.7% | +8.0% | +31.4% | -8.2% | +12.3% | +3.0% | +21.9% | -6.3% | +15.0% | +13.1% | +6.8% | +5.2% | +8.2% |
| YoY Change | — | — | — | — | +16.7% | +47.8% | +31.5% | +55.6% | +57.1% | +60.6% | +52.1% | +46.4% | +39.7% | +29.6% | +32.2% | +35.4% | +48.5% | +30.1% | +46.1% | +37.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's lorbrena — revenues:?
- Pfizer (PFE) reported lorbrena — revenues: of $305.00M in Q1 2026.
- How has Pfizer's lorbrena — revenues: changed year-over-year?
- Pfizer's lorbrena — revenues: increased by 37.4% year-over-year, from $222.00M to $305.00M.
- What is the long-term trend for Pfizer's lorbrena — revenues:?
- Over 4 years (2021 to 2025), Pfizer's lorbrena — revenues: has grown at a 40.0% compound annual growth rate (CAGR), from $266.00M to $1.02B.
- What does lorbrena — revenues: mean?
- The total revenue generated from the sales of a specific oncology drug product.